← ANALYST RATINGS · TIPRANKS
Century Therapeutics (IPSC): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $5.90, the highest $8.00, the lowest $4.00. The average is +330.7% from the last price of $1.37.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $4.00 | Buy | +192.0% | Reiterated | 06.10.26on TipRanks 06:50 | −11.4%next day −2.8% · 5 days +4.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +9.5% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | +9.5% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +9.5% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 | Hold | +9.5% | Upgrade | 30.09.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +9.5% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Hold | +9.5% | Reiterated | 30.09.26on TipRanks 01:05 | — | |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $8.00 | Buy | +483.9% | Reiterated | 17.08.26on TipRanks 12:10 | +2.0%next day +1.2% · 5 days +9.9% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $5.00 | Buy | +265.0% | Reiterated | 13.08.26on TipRanks 06:30 | −2.2%next day −0.3% · 5 days +6.6% | ↗ |
| Unknown Analyst | Clear Street | $6.60 | Buy | +381.8% | Reiterated | 13.08.26on TipRanks 06:30 | −2.2%next day −0.3% · 5 days +6.6% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 12.08.26on TipRanks Aug 13 10:35 | −5.1%next day −2.2% · 5 days +8.1% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $7.00 → $2.00−71.4% | Hold | +46.0% | Downgrade | 17.11.25on TipRanks 06:30 | +2.6%next day +2.9% · 5 days +7.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Century Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.53 at a price of $1.71 (+282.1%); now: $5.90 at $1.37 (+330.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 7 | 6 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.12 (from $-0.12 to $-0.12). Last quarter: $-0.17.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Century Therapeutics
- CEO: Brent Pfeiffenberger
- Employees: 78
- 25 North 38th Street, Philadelphia, PA, 19104, US
- www.centurytx.com
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 97 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗